On November 4, 2025, Evoke announced that it has entered into an agreement and plan of merger (the "Merger Agreement”) with ...

Silexion continues to advance operational readiness for its planned Phase 2/3 clinical trials of SIL204, with toxicology ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...

Dye & Durham Limited (the “Company” or “Dye & Durham”) (TSX: DND) today announced preliminary unaudited results for the ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...

CNW/ - Thinkific Labs Inc. ("Thinkific" or the "Company") (TSX: THNC), a leading learning commerce platform, today announced ...

Evernorth Holdings Inc. ("Evernorth"), a newly formed Nevada corporation that will enable XRP adoption on an institutional ...

TORONTO, Nov. 3, 2025 /CNW/ – . (“Corus” or the “Company”) (TSX: CJR.B) today announced a proposed recapitalization transaction (the “Recapitalization Transaction”) that ...

Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

Figma, Inc. (NYSE:FIG) announced financial results today for its third quarter ended September 30, 2025. "Q3 was the best ...

Trvsthub™ Roadmap: SSI as the Backbone for Secure, Instant Transactions. Trvsthub™ will be an open-source, ...